Gudo ES, Silva-Barbosa SD, Linhares-Lacerda L, Ribeiro-Alves M, Real SC, Bou-Habib DC, Savino W
Lasting success comes from using the medication window to reverse insulin resistance and build a new metabolic reality
For IGF-1 LR3, this is almost never practical
The opportunity The data points to a major expansion opportunity for oral GLP-1s in the UK market, particularly among younger adults and treatment-hesitant patients
By causing more weight loss and lowering inflammation, blood sugar, cholesterol, and liver fat , these medicines can reduce risks for heart disease, diabetes, and fatty liver disease
Most studies did not report changes in waist circumference